← 返回

头颈部鳞状细胞癌诊断和预后相关糖基转移酶基因的开发与验证

英文原题:Development and validation of glycosyltransferase related-gene for the diagnosis and prognosis of head and neck squamous cell carcinoma.

查看英文原题

Development and validation of glycosyltransferase related-gene for the diagnosis and prognosis of head and neck squamous cell carcinoma.

PubMed 2024/01/19(内容时间) Aging (Albany NY)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们建立了两种新的生物标志物,可为 HNSCC 患者的诊断、预后及治疗提供临床指导。

研究思路结论见上方概要

头颈部鳞状细胞癌(HNSCC)是一种高度异质性的癌症,其特点是早期诊断和预后预测困难。糖基转移酶异常表达所产生的异常糖基化结构在HNSCC中普遍存在。在本研究中,我们旨在构建具有诊断和预后价值的糖基转移酶相关基因特征,以更好地对HNSCC患者进行分层,并改善其诊断和预后。

采用生物信息学工具处理来自癌症基因组图谱(TCGA)数据库中HNSCC患者的数据。使用单因素和多因素Cox回归方法构建预后模型,同时使用支持向量机(SVM)和LASSO分析构建诊断特征。结果通过基因表达综合数据库(GEO)队列进行验证。分析了由糖基转移酶相关基因定义的亚组中的肿瘤微环境和免疫检查点抑制剂(ICI)治疗的获益。进行了分子生物学实验,包括western blotting、细胞计数试剂盒(CCK)-8、集落形成、伤口愈合和Transwell实验,以证实beta-1,4-半乳糖基转移酶3(B4GALT3)在HNSCC中的致癌功能。

我们建立了一个五基因预后特征和一个15基因诊断模型。根据中位风险评分,低风险患者的总生存期长于高风险组,这与GEO队列的结果一致。具体结果表明,高风险样本与高肿瘤蛋白(TP)53突变率、静息记忆分化簇(CD)4 T细胞、静息自然杀伤(NK)细胞和M0巨噬细胞的高浸润相关,并从ICI治疗中获益。相反,低风险亚组与低TP53突变率相关;以及幼稚B细胞、浆细胞、CD8 T细胞和静息肥大细胞的高浸润;从ICI治疗中获益较少。此外,诊断模型在训练数据集和验证队列中的曲线下面积(AUC)值分别为0.997和0.978,表明该模型具有很高的诊断潜力。最终,B4GALT3的缺失显著阻碍了HNSCC细胞的增殖、迁移和侵袭。

展开英文摘要原文

Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous cancer characterized by difficulties in early diagnosis and outcome prediction. Aberrant glycosylated structures produced by the aberrant expression of glycosyltransferases are prevalent in HNSCC. In this study, we aim to construct glycosyltransferase-related gene signatures with diagnostic and prognostic value to better stratify patients with HNSCC and improve their diagnosis and prognosis.

Bioinformatic tools were used to process data of patients with HNSCC from The Cancer Genome Atlas (TCGA) database. The prognostic model was formatted using univariate and multivariate Cox regression methods, while the diagnostic signature was constructed using support vector machine (SVM) and LASSO analysis. The results were verified using the Gene Expression Omnibus (GEO) cohort. The tumor microenvironment and benefits of immune checkpoint inhibitor (ICI) therapy in subgroups defined by glycosyltransferase-related genes were analyzed. Molecular biology experiments, including western blotting, cell counting kit (CCK)-8, colony formation, wound healing, and Transwell assays, were conducted to confirm the oncogenic function of beta-1,4-galactosyltransferase 3 (B4GALT3) in HNSCC.

We established a five-gene prognostic signature and a 15-gene diagnostic model. Based on the median risk score, patients with low risk had longer overall survival than those in the high-risk group, which was consistent with the results of the GEO cohort. The concrete results suggested that high-risk samples were related to a high tumor protein (TP)53 mutation rate, high infiltration of resting memory cluster of differentiation (CD)4 T cells, resting natural killer (NK) cells, and M0 macrophages, and benefited from ICI therapy. In contrast, the low-risk subgroup was associated with a low TP53 mutation rate; and high infiltration of naive B cells, plasma cells, CD8 T cells, and resting mast cells; and benefited less from ICI therapy. In addition, the diagnostic model had an area under curve (AUC) value of 0.997 and 0.978 in the training dataset and validation cohort, respectively, indicating the high diagnostic potential of the model. Ultimately, the depletion of B4GALT3 significantly hindered the proliferation, migration, and invasion of HNSCC cells.

We established two new biomarkers that could provide clinicians with diagnostic, prognostic, and treatment guidance for patients with HNSCC.

论文信息

作者
He M、Wang L、Yue Z、Feng C、Dai G、Jiang J、Huang H、Ji Q
单位
Department of Otorhinolaryngology, Head and Neck Surgery, The People’s Hospital of Bozhou, Bozhou 236000, Anhui, China.China
期刊
Aging2024 Jan 19
原文标识
PubMed 38244579 · DOI 10.18632/aging.205455